Switch Contrast

Seminar Series - Dr. Luca Peruzzotti-Jametti

17.12.2026, 13:00 Label 2026 Label News and Calendar

Succinate as a metabolic determinant of microglial function in CNS inflammation

About Dr. Peruzzotti-Jametti's talk:
Microglia, the resident innate immune cells of the central nervous system (CNS), drive the chronic inflammation and secondary neurotoxicity seen in many
progressive CNS disorders. Emerging evidence establishes cellular metabolism, particularly the tricarboxylic acid cycle intermediate succinate, as a central
determinant of microglial function, dictating the transition between homeostatic surveillance and persistent activation. We identify a distinct mitochondrial
dysregulation within pro-inflammatory microglia, characterised by defective oxidative phosphorylation and a shift toward reverse electron transport. Succinate
oxidation, coupled with increased complex I activity, repurposes mitochondria from ATP production toward neurotoxic ROS generation. Inhibiting this pathway
prevents secondary neuronal damage in vitro and in vivo. Concurrently, we show that succinate is released into the extracellular space to engage its cognate
receptor SUCNR1, reinforcing a pro-inflammatory phenotype and establishing a self-perpetuating inflammatory loop. Antagonising SUCNR1 attenuates
cytokine production, CNS immune infiltration, and axonal damage, thereby ameliorating disease outcomes. These mechanisms are conserved in human
microglia and pathological tissue states, operating within a landscape of marked spatial and temporal metabolic heterogeneity. Collectively, succinate-driven
mitochondrial and signalling pathways emerge as targetable determinants of microglial function and promising therapeutic avenues for chronic CNS disease.

Scientific Background:
Luca Peruzzotti-Jametti obtained his MD from the University Vita-Salute San Raffaele of Milan, Italy (2007), where he completed a residency program in
Neurology (2013). Following a PhD in Clinical Neurosciences at the University of Cambridge, UK (2018), he progressed towards a post-doctoral position at
Cambridge University and became Group Leader within the CCMR (2022) and Department of Clinical Neurosciences (2024), where he also serves as
Honorary Neurology Consultant.
Over the last 10+ years, Luca has made key contributions to the understanding of central nervous system diseases. His research in neuroimmunology led to
novel experimental advanced therapeutics for the treatment of ischemic stroke, spinal cord injury, and multiple sclerosis. His current work is focusing on
cellular metabolism to find novel ways to modulate chronic inflammation and favour CNS regeneration.
Luca is a 2015 Wellcome Trust RT Fellow, a 2020 Wellcome Trust CRCD Fellow, and a 2024 MRC Clinician Scientist Fellow. He was the recipient of the 2018
CSAR PhD Student Award for Applied Research, the 2018 Italian Embassy Italy Made Me Award in Life Sciences, the 2020 UK Society for Extracellular
Vesicles Young Investigator award, and the 2022 Rita Levi Montalcini award for Multiple Sclerosis research.
Lab website: https://www.LPJlab.org/

Host: PhD student representatives (MPI AGE)

Telephone BookCECAD on BlueskyCECAD on FacebookCECAD on YoutubeCECAD on LinkedIn